# GLP-1 “microdosing” for maintenance: what is established?

Maintenance trials support continued treatment in specific regimens. They do not establish that any tiny dose or intermittent schedule will preserve results.

Canonical: https://velri.co/blog/glp1-microdose-maintenance-goal-weight-provider-watches
Publisher: Velri (https://velri.co/about)
Published: 2026-07-17
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

The term “microdosing” is not enough to identify a maintenance plan. It may be used to describe a smaller amount, a longer interval between doses or another departure from a standard regimen. The actual product and prescribed schedule are what can be evaluated.

Approved semaglutide and tirzepatide labels define specific maintenance regimens and direct clinicians to consider treatment response and tolerability. They do not define a separate “microdosing” category. [1][2]

## What do maintenance trials support?

SURMOUNT-4 compared continuing tirzepatide with switching to placebo after an initial treatment period. Continued treatment maintained and added to the initial weight reduction, while withdrawal led to substantial regain on average. [3]

The trial did not compare continued treatment with smaller doses or longer intervals between doses, so it cannot establish how those approaches would perform. [3]

The semaglutide STEP 1 extension likewise followed people after treatment and the lifestyle intervention stopped. It found substantial average regain, but it did not test microdosing as an alternative. [4]

## What would make a proposed plan reviewable?

A meaningful explanation should identify the ingredient, formulation, intended regimen and evidence being used. It should also say how benefit and tolerability will be assessed and what would prompt a reassessment. [1][2]

## Why compounded products add another distinction

Compounded drugs are not FDA approved, and the FDA does not review their safety, effectiveness or quality before marketing. Evidence for an approved product should not be treated as proof of equivalent performance from a different compounded preparation. [5]

The FDA has also reported dosing errors involving compounded injectable semaglutide, including confusion about concentrations and syringe units. A smaller intended amount still requires exact, product-specific instructions. [6]

## Sources
[1] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[2] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[3] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. (2024). https://pubmed.ncbi.nlm.nih.gov/38078870/
[4] Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. (2022). https://pubmed.ncbi.nlm.nih.gov/35441470/
[5] Compounding and the FDA: Questions and Answers | FDA (2025). https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
[6] FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products | FDA (2024). https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support